MDWD
Price
$17.64
Change
+$0.10 (+0.57%)
Updated
Oct 8, 04:59 PM (EDT)
Capitalization
224.89M
41 days until earnings call
PHIO
Price
$2.43
Change
+$0.08 (+3.40%)
Updated
Oct 8, 04:56 PM (EDT)
Capitalization
13.86M
Interact to see
Advertisement

MDWD vs PHIO

Header iconMDWD vs PHIO Comparison
Open Charts MDWD vs PHIOBanner chart's image
MediWound
Price$17.64
Change+$0.10 (+0.57%)
Volume$1.46K
Capitalization224.89M
Phio Pharmaceuticals
Price$2.43
Change+$0.08 (+3.40%)
Volume$200
Capitalization13.86M
MDWD vs PHIO Comparison Chart in %
MDWD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDWD vs. PHIO commentary
Oct 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDWD is a Hold and PHIO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 09, 2025
Stock price -- (MDWD: $17.54 vs. PHIO: $2.35)
Brand notoriety: MDWD and PHIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDWD: 41% vs. PHIO: 29%
Market capitalization -- MDWD: $224.89M vs. PHIO: $13.86M
MDWD [@Biotechnology] is valued at $224.89M. PHIO’s [@Biotechnology] market capitalization is $13.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDWD’s FA Score shows that 1 FA rating(s) are green whilePHIO’s FA Score has 0 green FA rating(s).

  • MDWD’s FA Score: 1 green, 4 red.
  • PHIO’s FA Score: 0 green, 5 red.
According to our system of comparison, PHIO is a better buy in the long-term than MDWD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDWD’s TA Score shows that 4 TA indicator(s) are bullish while PHIO’s TA Score has 6 bullish TA indicator(s).

  • MDWD’s TA Score: 4 bullish, 6 bearish.
  • PHIO’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PHIO is a better buy in the short-term than MDWD.

Price Growth

MDWD (@Biotechnology) experienced а -2.66% price change this week, while PHIO (@Biotechnology) price change was -5.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.11%. For the same industry, the average monthly price growth was +19.03%, and the average quarterly price growth was +87.04%.

Reported Earning Dates

MDWD is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+9.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDWD($225M) has a higher market cap than PHIO($13.9M). PHIO YTD gains are higher at: 30.556 vs. MDWD (-1.461). PHIO has higher annual earnings (EBITDA): -7.45M vs. MDWD (-30.62M). MDWD has more cash in the bank: 32.4M vs. PHIO (10.8M). PHIO has less debt than MDWD: PHIO (0) vs MDWD (8.07M). MDWD has higher revenues than PHIO: MDWD (19.9M) vs PHIO (0).
MDWDPHIOMDWD / PHIO
Capitalization225M13.9M1,619%
EBITDA-30.62M-7.45M411%
Gain YTD-1.46130.556-5%
P/E RatioN/A0.01-
Revenue19.9M0-
Total Cash32.4M10.8M300%
Total Debt8.07M0-
FUNDAMENTALS RATINGS
MDWD vs PHIO: Fundamental Ratings
MDWD
PHIO
OUTLOOK RATING
1..100
158
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
5447
P/E GROWTH RATING
1..100
463
SEASONALITY SCORE
1..100
507

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PHIO's Valuation (50) in the Biotechnology industry is in the same range as MDWD (70) in the Pharmaceuticals Other industry. This means that PHIO’s stock grew similarly to MDWD’s over the last 12 months.

PHIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MDWD (100) in the Pharmaceuticals Other industry. This means that PHIO’s stock grew similarly to MDWD’s over the last 12 months.

PHIO's SMR Rating (99) in the Biotechnology industry is in the same range as MDWD (99) in the Pharmaceuticals Other industry. This means that PHIO’s stock grew similarly to MDWD’s over the last 12 months.

PHIO's Price Growth Rating (47) in the Biotechnology industry is in the same range as MDWD (54) in the Pharmaceuticals Other industry. This means that PHIO’s stock grew similarly to MDWD’s over the last 12 months.

MDWD's P/E Growth Rating (4) in the Pharmaceuticals Other industry is somewhat better than the same rating for PHIO (63) in the Biotechnology industry. This means that MDWD’s stock grew somewhat faster than PHIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDWDPHIO
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 9 days ago
83%
Declines
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
MDWD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RHEP1.70N/A
+0.18%
Regional Health Properties, Inc.
NTTDF6144706000.00N/A
N/A
NTT DATA GROUP CORPORATION
ORPB10.60N/A
N/A
Oregon Pacific Bancorp
RICOF9.10N/A
N/A
Ricoh Company Ltd.
JXFGF0.28N/A
N/A
JINXIN FERTILITY GROUP LTD.